person · Reporting owner
Chudnovsky Yekaterina
Disclosed activity across 3 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Elicio Therapeutics, Inc.ELTX · Entity 299 | Director · 10% owner | August 31, 2026 | September 02, 2026 |
| Immix Biopharma, Inc.IMMX · Entity 4958 | Director | May 22, 2026 | May 29, 2026 |
| Xilio Therapeutics, Inc.XLO · Entity 7122 | 10% owner | June 07, 2024 | September 28, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Elicio Therapeutics, Inc.
Report date August 31, 2026 · Filed September 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.70 · Expires 2036-08-31 | Direct | 21,750 |
Reported balance
After 2026-08-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-31 · Grant · Acquired 21,750 · Balance 21,750 F1: The stock option represents the annual non-employee director equity award to the Reporting Person and shall vest and become exercisable in full on the earlier of (A) August 31, 2027, the one-year anniversary of the date of grant, and (B) the annual meeting of the Issuer's stockholders held in 2027, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. No additional equity award will be made to the Reporting Person in connection with the 2026 annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option represents the annual non-employee director equity award to the Reporting Person and shall vest and become exercisable in full on the earlier of (A) August 31, 2027, the one-year anniversary of the date of grant, and (B) the annual meeting of the Issuer's stockholders held in 2027, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. No additional equity award will be made to the Reporting Person in connection with the 2026 annual meeting of stockholders.
Immix Biopharma, Inc.
Report date May 22, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,250 |
Reported balance
After 2026-05-22 transaction · row 1
1 source rowRow 1 · 2026-05-22 · Grant · Acquired 6,250 · Balance 6,250 F1: The Reporting Person was granted 6,250 restricted stock units ("RSUs") pursuant to the Issuer's 2021 Equity Incentive Plan, which RSUs will vest in full on the earlier of (i) the one-year anniversary of the date of grant, and (ii) the date that the Issuer's 2027 annual meeting of stockholders (the "2027 Annual Meeting") is held, subject to the Reporting Person's continued service with the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.78 · Expires 2036-05-22 | Direct | 12,500 |
Reported balance
After 2026-05-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-22 · Grant · Acquired 12,500 · Balance 12,500 F3: The stock option will vest in substantially equal monthly installments over the 12 months following the date of grant (or, in the event the 2027 Annual Meeting occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the stock option will vest on the date of such 2027 Annual Meeting), subject to the Reporting Person's continued service on the Issuer's Board through the applicable vesting date. |
| Common StockSEC Table I · non-derivative | IndirectHeld by GKCC, LLC | 3,241,076 |
Reported balance
Holding disclosure · report date 2026-05-22 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 3,241,076 F2: The Reporting Person is the sole member and manager of GKCC, LLC and may be deemed to beneficially own the shares held by GKCC, LLC. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted 6,250 restricted stock units ("RSUs") pursuant to the Issuer's 2021 Equity Incentive Plan, which RSUs will vest in full on the earlier of (i) the one-year anniversary of the date of grant, and (ii) the date that the Issuer's 2027 annual meeting of stockholders (the "2027 Annual Meeting") is held, subject to the Reporting Person's continued service with the Issuer.
F2: The Reporting Person is the sole member and manager of GKCC, LLC and may be deemed to beneficially own the shares held by GKCC, LLC.
F3: The stock option will vest in substantially equal monthly installments over the 12 months following the date of grant (or, in the event the 2027 Annual Meeting occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the stock option will vest on the date of such 2027 Annual Meeting), subject to the Reporting Person's continued service on the Issuer's Board through the applicable vesting date.
Xilio Therapeutics, Inc.
Report date June 07, 2024 · Filed September 28, 2024
Jointly reported with GKCC, LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectHeld by GKCC, LLC | 7,000,000 |
Reported balance
Holding disclosure · report date 2024-06-07 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 7,000,000 F1: Yekaterina (Katie) Chudnovsky is the sole member and manager of GKCC, LLC and may be deemed to beneficially own the shares held by GKCC, LLC. |
Filing footnotes · ownership attribution and instrument terms
F1: Yekaterina (Katie) Chudnovsky is the sole member and manager of GKCC, LLC and may be deemed to beneficially own the shares held by GKCC, LLC.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 31, 2026 Filed Sep 2, 2026 20:04 UTC | Elicio Therapeutics, Inc. ELTX · Entity 299 | GrantStock Option (Right to Buy) · Derivative | 21,750 | $0.00 Strike: $2.70 | $0.00 |
DisclosureSEC source: 0001979324-26-000002 · wk-form4_1788379464.xml · derivative · entry 1 Chudnovsky Yekaterina · CIK 0001979324 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,750 Underlying: Common Stock · 21,750 shares Expires 2036-08-31 F1 · derivative.exercise_date: The stock option represents the annual non-employee director equity award to the Reporting Person and shall vest and become exercisable in full on the earlier of (A) August 31, 2027, the one-year anniversary of the date of grant, and (B) the annual meeting of the Issuer's stockholders held in 2027, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. No additional equity award will be made to the Reporting Person in connection with the 2026 annual meeting of stockholders. Read SEC document |
| May 22, 2026 Filed May 29, 2026 21:05 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $8.78 | $0.00 |
DisclosureSEC source: 0001493152-26-026424 · ownership.xml · derivative · entry 3 Chudnovsky Yekaterina · CIK 0001979324 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2036-05-22 F3 · derivative.exercise_date: The stock option will vest in substantially equal monthly installments over the 12 months following the date of grant (or, in the event the 2027 Annual Meeting occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the stock option will vest on the date of such 2027 Annual Meeting), subject to the Reporting Person's continued service on the Issuer's Board through the applicable vesting date. Read SEC document |
| May 22, 2026 Filed May 29, 2026 21:05 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | GrantCommon Stock | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-026424 · ownership.xml · nonDerivative · entry 1 Chudnovsky Yekaterina · CIK 0001979324 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,250 F1 · shares: The Reporting Person was granted 6,250 restricted stock units ("RSUs") pursuant to the Issuer's 2021 Equity Incentive Plan, which RSUs will vest in full on the earlier of (i) the one-year anniversary of the date of grant, and (ii) the date that the Issuer's 2027 annual meeting of stockholders (the "2027 Annual Meeting") is held, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| June 20, 2025 Filed Jun 23, 2025 20:57 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | GrantStock Option (Right to Buy) · Derivative | 33,000 | $0.00 Strike: $2.24 | $0.00 |
DisclosureSEC source: 0001641172-25-016111 · ownership.xml · derivative · entry 2 Chudnovsky Yekaterina · CIK 0001979324 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,000 Underlying: Common Stock · 33,000 shares Expires 2035-06-20 F2 · derivative.exercise_date: The Stock Option will vest in twelve (12) equal monthly installments following the date of grant, subject to the Reporting Person's continued service on the Board of Directors. Read SEC document |
| June 03, 2025 Filed Jun 4, 2025 21:08 UTC | Elicio Therapeutics, Inc. ELTX · Entity 299 | GrantWarrant (right to buy) · Derivative | 103,225 | $0.00 Strike: $7.75 | $0.00 |
DisclosureSEC source: 0000950170-25-081741 · ownership.xml · derivative · entry 1 Chudnovsky Yekaterina · CIK 0001979324 · Director · 10% owner GKCC, LLC · CIK 0001977769 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Held by GKCC, LLC Disclosed balance after: 103,225 Underlying: Common Stock · 103,225 shares Expires 2030-06-03 F1 · ownership.nature: Yekaterina (Katie) Chudnovsky is the sole member and manager of GKCC, LLC and may be deemed to beneficially own the shares held by GKCC, LLC. Read SEC document |
| May 19, 2025 Filed May 20, 2025 20:05 UTC | Elicio Therapeutics, Inc. ELTX · Entity 299 | GrantStock Option (Right to Buy) · Derivative | 7,900 | $0.00 Strike: $5.84 | $0.00 |
DisclosureSEC source: 0001601485-25-000084 · wk-form4_1747771529.xml · derivative · entry 1 Chudnovsky Yekaterina · CIK 0001979324 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,900 Underlying: Common Stock · 7,900 shares Expires 2035-05-19 F1 · shares: The stock option shall vest and become exercisable in full on the earlier of (A) May 19, 2026, the one-year anniversary of the date of grant and (B) the next annual meeting of the Company's stockholders after the grant date, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. F1 · derivative.exercise_date: The stock option shall vest and become exercisable in full on the earlier of (A) May 19, 2026, the one-year anniversary of the date of grant and (B) the next annual meeting of the Company's stockholders after the grant date, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 21:06 UTC | Elicio Therapeutics, Inc. ELTX · Entity 299 | ConversionConvertible Note (convertible into Common Stock) · Derivative | 3,442,341 | $5.81 Strike: $5.81 | $20,000,001.21 |
DisclosureSEC source: 0000950170-25-035494 · ownership.xml · derivative · entry 2 Chudnovsky Yekaterina · CIK 0001979324 · Director · 10% owner GKCC, LLC · CIK 0001977769 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Held by GKCC, LLC Disclosed balance after: 0 Underlying: Common Stock · 3,442,341 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The Convertible Note had a stated maturity date of February 15, 2026. The Convertible Note, including any accrued but unpaid interest, was converted into shares of Common Stock on March 5, 2025 at a conversion price of $5.81 per share. F2 · derivative.expiration_date: The Convertible Note had a stated maturity date of February 15, 2026. The Convertible Note, including any accrued but unpaid interest, was converted into shares of Common Stock on March 5, 2025 at a conversion price of $5.81 per share. F1 · ownership.nature: Yekaterina (Katie) Chudnovsky is the sole member and manager of GKCC, LLC and may be deemed to beneficially own the shares held by GKCC, LLC. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 21:06 UTC | Elicio Therapeutics, Inc. ELTX · Entity 299 | ConversionCommon Stock | 3,500,573 | $5.81 | $20,338,329.13 |
DisclosureSEC source: 0000950170-25-035494 · ownership.xml · nonDerivative · entry 1 Chudnovsky Yekaterina · CIK 0001979324 · Director · 10% owner GKCC, LLC · CIK 0001977769 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Held by GKCC, LLC Disclosed balance after: 5,416,212 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: Yekaterina (Katie) Chudnovsky is the sole member and manager of GKCC, LLC and may be deemed to beneficially own the shares held by GKCC, LLC. Read SEC document |
| November 21, 2024 Filed Nov 25, 2024 12:33 UTC | Elicio Therapeutics, Inc. ELTX · Entity 299 | GrantStock Option (Right to Buy) · Derivative | 4,100 | $0.00 Strike: $5.12 | $0.00 |
DisclosureSEC source: 0001601485-24-000091 · wk-form4_1732537993.xml · derivative · entry 1 Chudnovsky Yekaterina · CIK 0001979324 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,100 Underlying: Common Stock · 4,100 shares Expires 2034-11-21 F1 · shares: The stock option shall vest and become exercisable in full on the earlier of (A) November 21, 2025, the one-year anniversary of the date of grant and (B) the next annual meeting of the Company's stockholders after the grant date, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. F1 · derivative.exercise_date: The stock option shall vest and become exercisable in full on the earlier of (A) November 21, 2025, the one-year anniversary of the date of grant and (B) the next annual meeting of the Company's stockholders after the grant date, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 20:41 UTC | Elicio Therapeutics, Inc. ELTX · Entity 299 | PurchaseConvertible Note (convertible into Common Stock) · Derivative | 3,442,341 | $5.81 Strike: $5.81 | $20,000,001.21 |
DisclosureSEC source: 0001140361-24-037346 · form4.xml · derivative · entry 1 Chudnovsky Yekaterina · CIK 0001979324 · Director · 10% owner GKCC, LLC · CIK 0001977769 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Held by GKCC, LLC Disclosed balance after: 3,442,341 Underlying: Common Stock · 3,442,341 shares Expires not disclosed F1 · shares: On August 12, 2024, GKCC, LLC (the "Purchaser") purchased from the Issuer a convertible note with an aggregate principal amount of $20,000,000 (the "Convertible Note"). The Convertible Note is convertible into shares of common stock of the Issuer at a conversion price of $5.81 per share, subject to adjustment in certain circumstances. Therefore, the Convertible Note is initially convertible into approximately 3,442,341 shares of common stock of the Issuer. F2 · derivative.exercise_date: The Convertible Note will mature on February 15, 2026, unless earlier converted in accordance with the terms of the Convertible Note. Interest on the Convertible Note is payable in cash and will accrue and be payable quarterly on the principal amount equal to 3% per annum. F2 · derivative.expiration_date: The Convertible Note will mature on February 15, 2026, unless earlier converted in accordance with the terms of the Convertible Note. Interest on the Convertible Note is payable in cash and will accrue and be payable quarterly on the principal amount equal to 3% per annum. F3 · ownership.nature: Yekaterina (Katie) Chudnovsky is the sole member and manager of the Purchaser and may be deemed to beneficially own the shares held by the Purchaser. Read SEC document |
| June 28, 2024 Filed Jul 2, 2024 20:30 UTC | Elicio Therapeutics, Inc. ELTX · Entity 299 | PurchasePre-Funded Warrants · Derivative | 1,600,000 | $4.99 Strike: $0.01 | $7,984,000.00 |
DisclosureSEC source: 0001140361-24-032163 · form4.xml · derivative · entry 2 Chudnovsky Yekaterina · CIK 0001979324 · Director · 10% owner GKCC, LLC · CIK 0001977769 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,600,000 Underlying: Common Stock · 1,600,000 shares Expires not disclosed F3 · derivative.exercise_date: Each Pre-Funded Warrant will be exercisable by the holder at any time on or after July 1, 2024 at an exercise price equal to $0.01 per share, subject to adjustments as provided under the terms of the Pre-Funded Warrant, subject to a post-exercise beneficial ownership limitation of 19.99%. F4 · derivative.expiration_date: The Pre-Funded Warrants do not have an expiration date. Read SEC document |
| June 28, 2024 Filed Jul 2, 2024 20:30 UTC | Elicio Therapeutics, Inc. ELTX · Entity 299 | PurchaseCommon Warrants · Derivative | 1,600,000 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001140361-24-032163 · form4.xml · derivative · entry 1 Chudnovsky Yekaterina · CIK 0001979324 · Director · 10% owner GKCC, LLC · CIK 0001977769 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,600,000 Underlying: Common Stock · 1,600,000 shares Expires not disclosed F1 · derivative.exercise_date: Each Common Warrant will be exercisable by the holder at any time on or after July 1, 2024 at an exercise price equal to $5.00 per share, subject to adjustments as provided under the terms of the Common Warrant, subject to a post-exercise beneficial ownership limitation of 19.99%. F2 · derivative.expiration_date: The Common Warrants expire on July 1, 2029. Read SEC document |
| June 11, 2024 Filed Jun 21, 2024 21:45 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | GrantStock Option (Right to Buy) · Derivative | 33,000 | $0.00 Strike: $2.04 | $0.00 |
DisclosureSEC source: 0001493152-24-024823 · ownership.xml · derivative · entry 2 Chudnovsky Yekaterina · CIK 0001979324 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,000 Underlying: Common Stock · 33,000 shares Expires 2034-06-11 F2 · derivative.exercise_date: The Stock Option will vest in twelve (12) equal monthly installments following the date of grant, subject to the Reporting Person's continued service on the Board of Directors. Read SEC document |
| March 19, 2024 Filed Mar 20, 2024 20:28 UTC | Elicio Therapeutics, Inc. ELTX · Entity 299 | PurchasePre-Funded Common Stock Purchase Warrant · Derivative | 1,032,702 | $5.81 Strike: $0.01 | $5,999,998.62 |
DisclosureSEC source: 0000950170-24-034198 · ownership.xml · derivative · entry 1 Chudnovsky Yekaterina · CIK 0001979324 · Director · 10% owner GKCC, LLC · CIK 0001977769 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Held by GKCC, LLC Disclosed balance after: 1,032,702 Underlying: Common Stock · 1,032,702 shares Expires not disclosed F1 · derivative.exercise_date: Each Pre-Funded Warrant will be exercisable by GKCC, LLC at any time on or after March 19, 2024 at an exercise price equal to $0.01 per share, subject to adjustments as provided under the terms of the Pre-Funded Warrant, subject to a post-exercise beneficial ownership limitation of 19.99%, unless stockholder approval is obtained. F2 · derivative.expiration_date: The Pre-Funded Warrants do not have an expiration date. F3 · ownership.nature: Yekaterina (Katie) Chudnovsky is the sole member and manager of GKCC, LLC and may be deemed to beneficially own the shares held by GKCC, LLC. Read SEC document |
| December 28, 2023 Filed Dec 29, 2023 22:05 UTC | Elicio Therapeutics, Inc. ELTX · Entity 299 | GrantStock Option (right to buy) · Derivative | 4,100 | $0.00 Strike: $8.26 | $0.00 |
DisclosureSEC source: 0001140361-23-060238 · form4.xml · derivative · entry 1 Chudnovsky Yekaterina · CIK 0001979324 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,100 Underlying: Common Stock · 4,100 shares Expires 2033-12-28 F1 · shares: The stock option, granted in lieu of the annual equity award under the Issuer's Amended and Restated Non-Employee Director Compensation Policy, vests in full on the earlier of (A) December 28, 2024, the one-year anniversary of the grant date, or (B) immediately prior to the next annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. F1 · derivative.exercise_date: The stock option, granted in lieu of the annual equity award under the Issuer's Amended and Restated Non-Employee Director Compensation Policy, vests in full on the earlier of (A) December 28, 2024, the one-year anniversary of the grant date, or (B) immediately prior to the next annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. Read SEC document |
| December 22, 2023 Filed Dec 26, 2023 21:29 UTC | Elicio Therapeutics, Inc. ELTX · Entity 299 | PurchaseCommon Stock | 1,213,000 | $5.81 | $7,047,530.00 |
DisclosureSEC source: 0001209191-23-059683 · doc4.xml · nonDerivative · entry 1 Chudnovsky Yekaterina · CIK 0001979324 · Director · 10% owner GKCC, LLC · CIK 0001977769 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Held by GKCC, LLC Disclosed balance after: 1,915,639 F1 · ownership.nature: Yekaterina (Katie) Chudnovsky is the sole member and manager of GKCC, LLC and may be deemed to beneficially own the shares held by GKCC, LLC. Read SEC document |
| August 22, 2023 Filed Aug 23, 2023 20:28 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | GrantStock Option (Right to Buy) · Derivative | 16,670 | $0.00 Strike: $1.80 | $0.00 |
DisclosureSEC source: 0001209191-23-047062 · doc4.xml · derivative · entry 2 Chudnovsky Yekaterina · CIK 0001979324 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,670 Underlying: Common Stock · 16,670 shares Expires 2033-08-22 F2 · derivative.exercise_date: The Stock Option will vest in ten (10) equal monthly installments following the date of grant and any remaining unvested shares will become fully vested and exercisable on the date of the 2024 annual shareholder meeting, subject to the Reporting Person's continued service on the Board of Directors. Read SEC document |
| August 22, 2023 Filed Aug 23, 2023 20:28 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $1.80 | $0.00 |
DisclosureSEC source: 0001209191-23-047062 · doc4.xml · derivative · entry 1 Chudnovsky Yekaterina · CIK 0001979324 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-08-22 F1 · derivative.exercise_date: The Stock Option will vest in thirty-six (36) equal monthly installments following the date of grant, subject to the Reporting Person's continued service on the Board of Directors. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.